Ventrus BioSciences (VTUS) Publishes Prior Phase 2b Study on the Safety and Efficacy of Iferanserin
Go back to Ventrus BioSciences (VTUS) Publishes Prior Phase 2b Study on the Safety and Efficacy of Iferanserin| VENTRUS BIOSCIENCES (NASDAQ: VTUS) | Delayed: 1.45 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.45 | 52 Week High | $4.69 | |||
| Open | $6.60 | 52 Week Low | $0.85 | |||
| Day High | $1.45 | P/E | N/A | |||
| Day Low | $1.45 | EPS | $-0.99 | |||
| Volume | 247 | |||||
